UDK: 615.225.3:616.13.002.2-004.6
A.S. Netrebenko 1, V.V. Elagin 2, D.A. Kostina 1, V.V. Gureev 1, M.V. Pokrovsky 1, V.I. Yakushev 1, E.G. Saprykina 1, M.A. Zatolokina 2,3, T.V. Orlova 2
1Белгородский государственный национальный исследовательский университет, Белгород, Россия 2Курский государственный медицинский университет, Курск, Россия 3Орловский государственный университет имени И.С. Тургенева, Орел, Россия
The search for new drugs with cytoprotective and anti-ischemic activity is an urgent task of modern pharmacology. These properties are necessary for the complex protection of renal parenchyma during organ preservation operations (renal resection), most often carried out in conditions of thermal ischemia. Only the combined use of modern highly effective drugs and the skill of an operating surgeon can prevent the development of acute renal injury (AKI) due to pinching of renal vessels. The aim of this study was to investigate the nephroprotective effects of a combination of a peptide mimicking the α-helix B of erythropoietin (pHBSP) and infliximab in ischemic reperfusion damage to the kidneys. Methods. The experiment was conducted on 50 white laboratory male Wistar rats weighing 280–320 g. Animals were injected with a peptide mimicking the α-helix B of erythropoietin (pHBSP) and infliximab. Under anesthesia, atraumatic vascular clamps were applied to the left renal pedicle for 40 minutes, nephrectomy on the right. Functional samples and laboratory tests were performed 5 minutes and 72 hours after reperfusion. Results. As a result of the study, it was shown that using a combination of the peptide simulating α-helix B erythropoietin (pHBSP) and infliximab in ischemic-reperfusion kidney injury showed significantly more pronounced nephroprotective effects than using the peptide mimicking α-helix B erythropoietin or infliximab in the mono mode. Conclusion.The results of the study show the promise of combined use of peptide simulating α-helix B erythropoietin (pHBSP) and infliximab in order to correct ischemic-reperfusion kidney injuries.
pHBSP, infliximab, renal ischemia-reperfusion injury, microcirculation
Александр Сергеевич Нетребенко, AlexNetrebenko@mail.ru